Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, highlights the current challenges in treatment opportunities for multiple myeloma in Ireland, including limited access to clinical trials and limited availability of immunotherapies. Dr El Hassadi also emphasizes the challenges related to treating patients who relapse after several lines of therapy or who experience central nervous system (CNS) relapse. Dr El Hassadi further comments on emerging side effects related to novel agents for myeloma, which poses an issue by limiting prolonged exposure to the drug. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.